Anne Li 1/15/17
|
The National Cancer Institute (NCI) today launched a new drug formulary (the “NCI Formulary”) that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials. The NCI Formulary could ultimately translate into speeding the availability of more-effective treatment options to patients with cancer.
See original article at: https://www.cancer.gov/news-events/press-releases/2017/nci-formulary-launch |
Post a comment